Mirogabalin Besylate
Home / API - Under Development / Mirogabalin Besylate
Therapeutic Category
- Diabetic Neuropathy
Innovator Brand
GMP
Not Available
DMF
Not Available
Filed
-
Under Filing
-
Sample
Available
Indication
Mirogabalin Besylate is a medication developed by Daiichi Sankyo, a gabapentinoid, a Drug of Member class of Gabapentin and Pregabalin. As a gabapentinoid, mirogabalin binds to the α2δ subunit of voltage-gated calcium channel (1 and 2), but with significantly higher potency than Pregabalin.
Disclaimer: CTX Lifesciences respects patent laws and conventions of pharmaceuticals as applicable in different countries.
API/Substances covered by patent are not offered to the countries where the patent law is in force. However, the final responsibility lies with the customer.